Patient-Focused Drug Development: Is the Past Prologue?
PDUFA V introduced incentives for rare disease development but other key questions were unaddressed: how to include the patient voice and what is the proper role of advocacy groups, agencies, and industry? In the recent past, the patient voice was limited to teary anecdotes. Parent Project Muscular Dystrophy (PPMD), however, has made groundbreaking strides introducing the patient voice into the Duchenne muscular dystrophy development process – and giving other disease communities a blue print to follow. I had the opportunity to moderate a panel discussion with Pat Furlong, the Founding President and CEO of PPMD, about th...
Source: drugwonks.com Blog - September 6, 2007 Category: Pharmaceuticals Source Type: blogs
